GSTP1 Ile105Val and GPX1 Pro198Leu Polymorphisms
and Their Association with Response to Radiotherapy in
Nasopharyngeal Carcinoma Patients

El Benna, Naima; Tawfiq, Nezha; FILALI-MALTOUF, Abdelkarim; Benzeid, Rajaa; amina, gihbid; benider, abdellatif; chaoui, imane; GUENSI, AMAL; Benchakroun, Nadia; Khyatti, Meriem; El Mzibri, Mohammed; Attaleb, Mohammed

doi:10.14744/ejmo.2022.89238

GSTP1 Ile105Val and GPX1 Pro198Leu Polymorphisms and Their Association with Response to Radiotherapy in Nasopharyngeal Carcinoma Patients

Rajaa BENZEİD, (Biology Unit and Medical Research, National Center of Energy, Sciences and Nuclear Techniques, Rabat, Morocco)

Amina GIHBİD, (Laboratory of Viral Oncology, Pasteur Institute, Casablanca, Morocco)

Nadia BENCHEKROUN, (Department of Radiotherapy-Oncology, Mohammed VI Center for Treatment of Cancer, Ibn Rochd Hospital Center, Casablanca, Morocco)

Naima El BENNA, (Department of Radiology, Ibn Rochd University Hospital, Hopital 20 Août, Casablanca, Morocco)

Amal GUENSİ, (Department of Nuclear Medecine, Ibn Rochd University Hospital, Hassan II University, Casablanca, Morocco)

Abdellatif BENİDER, (4Department of Radiotherapy-Oncology, Mohammed VI Center for Treatment of Cancer, Ibn Rochd Hospital Center, Casablanca, Morocco)

Nezha TAWFİQ, (Department of Radiotherapy-Oncology, Mohammed VI Center for Treatment of Cancer, Ibn Rochd Hospital Center, Casablanca, Morocco)

Abdelkarim Filali MALTOUF, (Laboratory of Microbiology and Molecular Biology, Faculty of Sciences, Rabat, Morocco)

Mohammed El MZİBRİ, (Biology Unit and Medical Research, National Center of Energy, Sciences and Nuclear Techniques, Rabat, Morocco)

Mohammed ATTALEB, (Biology Unit and Medical Research, National Center of Energy, Sciences and Nuclear Techniques, Rabat, Morocco)

Meriem KHYATTİ, (Laboratory of Viral Oncology, Pasteur Institute, Casablanca, Morocco)

Imane CHAOUI, (Biology Unit and Medical Research, National Center of Energy, Sciences and Nuclear Techniques, Rabat, Morocco)

Diğer Yazarlar

Eurasian Journal of Medicine and Oncology

0 0

Yıl: 2022 Cilt: 6 Sayı: 1 Sayfa Aralığı: 64 - 72 Metin Dili: İngilizce DOI: 10.14744/ejmo.2022.89238 İndeks Tarihi: 18-06-2022

GSTP1 Ile105Val and GPX1 Pro198Leu Polymorphisms and Their Association with Response to Radiotherapy in Nasopharyngeal Carcinoma Patients

Öz:

Objectives: Radio-resistance poses a major challenge in nasopharyngeal carcinoma (NPC) treatment. Due to individual variations in radio-sensitivity, biomarkers are needed to tailor radiation treatment. Within this frame, the identification of series of genetic signatures mainly SNPs for NPC patients treated with radiotherapy may help to predict treatment outcome and deliver personalized therapy. The aim of this study was to evaluate the possible association between the GSTP1 Ile105Val and GPX1 Pro198Leu polymorphisms and response to radiotherapy in NPC patients. Methods: From September 2016 to October 2018, a total of 101 patients with confirmed NPC, recruited at Mohammed IV Center for Treatment of Cancer of Casablanca, underwent radiotherapy. DNA was extracted from peripheral blood. Genotyping of the GPX1 Pro198Leu and GPX1 Val105Leu polymorphisms was carried out by PCR amplification and DNA sequencing. SPSS was used to analyse the association of GSTP1 and GPX1 genotypes with clinico-pathological features and response to radiotherapy. Results: The genotyping data revealed the presence of only two genotypes namely Pro/Pro (57.4%) and Pro/Leu (40.6%) for GPX1 gene. The allelic frequencies of C and T alleles were 78.7% and 21.3% respectively. For GSTP gene, the homozygous genotypes Val/Val and Leu/Leu were detected in 35.6% and 12.9% of patients respectively. The heterozygous genotype Val/Leu prevailed (51.5%). Allelic frequencies showed the presence of the two alleles A and G in 57.1% and 42.9% patients respectively. Statistical analysis failed to find any significant association between GSTP Val105Ile and GPX1 Pro198Leu genetic polymorphisms and socio-demographic and clinico-pathological features as well as response to radiotherapy (p>0.05). Conclusion: Further research is warranted on the potential role of SNPs within antioxidant defines genes in radiotherapy response and to identify reliable predictive and non-invasive biomarkers for radio-resistance among NPC patients for personalised therapies.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Benider A, Harif M, Karkouri M, Quessar A, Sahraoui S, Sqalli S. Registre des Cancers de la région du Grand Casablanca pour la période 2008–2012. Lalla Salma Foundation; 2016. Available at : https://www.contrelecancer.ma/site_media/uploaded_ files/RCRGC.pdf. Accessed Mar 1, 2022.
2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394–424.
3. Shannon-Lowe C, Rickinson A. The global landscape of EBV-associated tumors. Front Oncol 2019;9:713.
4. Lee HM, Okuda KS, González FE, Patel V. Current perspectives on nasopharyngeal carcinoma. Adv Exp Med Biol 2019;1164:11–34.
5. Aksoy A, Elkiran ET, Harputluoglu H, Dagli AF, Isikdogan A, Urakci Z. Is excision repair cross-complementation Group1 expression a biological marker in nasopharynx carcinoma? J Cancer Res Ther 2019;15:550–5.
6. Li W, Chen J, Liu C. Glutathione S-transferase P1 Ile105Val polymorphism and oral cancer risk: a meta-analysis. Int J Med Sci 2013;10:392–8.
7. Rycaj K, Tang DG. Cancer stem cells and radioresistance. Int J Radiat Biol 2014;90:615–21.
8. Ameziane-El-Hassani R, Boufraqech M, Lagente-Chevallier O, Weyemi U, Talbot M, Métivier D, et al. Role of H2O2 in RET/ PTC1 chromosomal rearrangement produced by ionizing radiation in human thyroid cells. Cancer Res 2010;70:4123–32.
9. Bocedi A, Noce A, Marrone G, Noce G, Cattani G, Gambardella G, et al. Glutathione transferase P1-1 an enzyme useful in biomedicine and as biomarker in clinical practice and in environmental pollution. Nutrients 2019;11:1741.
10. Allocati N, Masulli M, Di Ilio C, Federici L. Glutathione transferases: substrates, inihibitors and pro-drugs in cancer and neurodegenerative diseases. Oncogenesis 2018;7:8.
11. Harries LW, Stubbins MJ, Forman D, Howard GC, Wolf CR. Identification of genetic polymorphisms at the glutathione S-transferase Pi locus and association with susceptibility to bladder, testicular and prostate cancer. Carcinogenesis 1997;18:641–4.
12. Morita S, Yano M, Tsujinaka T, Akiyama Y, Taniguchi M, Kaneko K, et al. Genetic polymorphisms of drug-metabolizing enzymes and susceptibility to head-and-neck squamous-cell carcinoma. Int J Cancer 1999;80:685–8.
13. Chen YL, Tseng HS, Kuo WH, Yang SF, Chen DR, Tsai HT. Glutathione S-Transferase P1 (GSTP1) gene polymorphism increases age-related susceptibility to hepatocellular carcinoma. BMC Med Genet 2010;11:46.
14. Ding F, Li JP, Zhang Y, Qi GH, Song ZC, Yu YH. Comprehensive Analysis of the Association Between the rs1138272 Polymorphism of the GSTP1 Gene and Cancer Susceptibility. Front Physiol 2019;9:1897.
15. Yadav P, Banerjee A, Boruah N, Singh CS, Chatterjee P, Mukherjee S, et al. Glutathione S-transferasesP1 AA (105Ile) allele increases oral cancer risk, interacts strongly with c-jun kinase and weakly detoxifies areca-nut metabolites. Sci Rep 2020;10:6032.
16. Al-Eitan LN, Rababa'h DM, Alghamdi MA, Khasawneh RH. Association Of GSTM1, GSTT1 And GSTP1 Polymorphisms With Breast Cancer Among Jordanian Women. Onco Targets Ther 2019;12:7757–65.
17. Farmohammadi A, Arab-Yarmohammadi V, Ramzanpour R. Association analysis of rs1695 and rs1138272 variations in GSTP1 gene and breast cancer susceptibility. Asian Pac J Cancer Prev 2020;21:1167–72.
18. Valko M, Rhodes CJ, Moncol J, Izakovic M, Mazur M. Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem Biol Interact 2006;160:1–40.
19. Lee CH, Lee KY, Choe KH, Hong YC, Noh SI, Eom SY, et al. Effects of oxidative DNA damage and genetic polymorphism of the glutathione peroxidase 1 (GPX1) and 8-oxoguanine glycosylase 1 (hOGG1) on lung cancer. J Prev Med Public Health 2006;39:130–4.
20. Ji M, Tang J, Zhao J, Xu B, Qin J, Lu J. Polymorphisms in genes involved in drug detoxification and clinical outcomes of anthracycline- based neoadjuvant chemotherapy in Chinese Han breast cancer patients. Cancer Biol Ther 2012;13:264–71.
21. Baroudi O, Benammar-Elgaaied A. Involvement of genetic factors and lifestyle on the occurrence of colorectal and gastric cancer. Crit Rev Oncol Hematol 2016;107:72–81.
22. Pérez S, Taléns-Visconti R, Rius-Pérez S, et al. Redox signaling in the gastrointestinal tract. Free Radic Biol Med 2017;104:75– 103.
23. Wang C, Zhang R, Chen N, Yang L, Wang Y, Sun Y, et al. Association between glutathione peroxidase-1 (GPX1) Rs1050450 polymorphisms and cancer risk. Int J Clin Exp Pathol 2017;10:9527–40.
24. Tulsyan S, Chaturvedi P, Agarwal G, Lal P, Agrawal S, Mittal RD, et al. Pharmacogenetic influence of GST polymorphisms on anthracycline-based chemotherapy responses and toxicity in breast cancer patients: a multi-analytical approach. Mol Diagn Ther 2013;17:371–9.
25. Deng X, Yang X, Cheng Y, Liu X, Li X, Zhao R, et al. GSTP1 and GSTO1 single nucleotide polymorphisms and the response of bladder cancer patients to intravesical chemotherapy. Sci Rep 2015;5:14000.
26. Pincinato EC, Costa EFD, Lopes-Aguiar L, Nogueira GAS, Lima TRP, Visacri MB, et al. GSTM1, GSTT1 and GSTP1 Ile105Val polymorphisms in outcomes of head and neck squamous cell carcinoma patients treated with cisplatin chemoradiation. Sci Rep 2019;9:9312.
27. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010;17:1471–4.
28. Petersson F. Nasopharyngeal carcinoma: a review. Semin Diagn Pathol 2015;32:54–73.
29. Holleczek B, Stegmaier C, Radosa JC, Solomayer EF, Brenner H. Brenner H. Risk of loco-regional recurrence and distant metastases of patients with invasive breast cancer up to ten years after diagnosis - results from a registry-based study from Germany. BMC Cancer 2019;19:520.
30. Zhan Y, Fan S. Multiple mechanisms involving in radioresistance of nasopharyngeal carcinoma. J Cancer 2020;11:4193– 204.
31. Guo Y, Zhu XD, Qu S, Li L, Su F, Li Y, et al. Identification of genes involved in radioresistance of nasopharyngeal carcinoma by integrating gene ontology and protein-protein interaction networks. Int J Oncol 2012;40:85–92.
32. Drobin K, Marczyk M, Halle M, Danielsson D, Papiez A, Sangsuwan T, et al. Molecular profiling for predictors of radiosensitivity in patients with breast or head-and-neck cancer. Cancers (Basel) 2020;12:753.
33. Jiang Y, Li N, Dong P, Zhang N, Sun Y, Han M, et al. Polymorphisms in GSTM1, GSTTI and GSTP1 and nasopharyngeal cancer in the East of China: a case-control study. Asian Pac J Cancer Prev 2011;12:3097–100.
34. Cao M, Mu X, Jiang C, Yang G, Chen H, Xue W. Single-nucleotide polymorphisms of GPX1 and MnSOD and susceptibility to bladder cancer: a systematic review and meta-analysis. Tumour Biol 2014;35:759–64.
35. Ratnasinghe D, Tangrea JA, Andersen MR, Barrett MJ, Virtamo J, Taylor PR, et al. Glutathione peroxidase codon 198 polymorphism variant increases lung cancer risk. Cancer Res 2000;60:6381–3.
36. Ichimura Y, Habuchi T, Tsuchiya N, Wang L, Oyama C, Sato K, et al. Increased risk of bladder cancer associated with a glutathione peroxidase 1 codon 198 variant. J Urol 2004;172:728–32.
37. Hu J, Zhou GW, Wang N, Wang YJ. GPX1 Pro198Leu polymorphism and breast cancer risk: a meta-analysis. Breast Cancer Res Treat 2010;124:425–31.
38. Hansen RD, Krath BN, Frederiksen K, Tjønneland A, Overvad K, Roswall N, et al. GPX1 Pro(198)Leu polymorphism, erythrocyte GPX activity, interaction with alcohol consumption and smoking, and risk of colorectal cancer. Mutat Res 2009;664:13–9.
39. Erdem O, Eken A, Akay C, Arsova-Sarafinovska Z, Matevska N, Suturkova L, et al. Association of GPX1 polymorphism, GPX activity and prostate cancer risk. Hum Exp Toxicol 2012;31:24– 31.
40. Yu Z, Li Z, Cai B, Wang Z, Gan W, Chen H, et al. Association between the GSTP1 Ile105Val polymorphism and prostate cancer risk: a systematic review and meta-analysis. Tumour Biol 2013;34:1855–63
41. Chatterjee A, Gupta S. The multifaceted role of glutathione S-transferases in cancer. Cancer Lett 2018;433:33–42.
42. Maniglia MP, Russo A, Biselli-Chicote PM, Oliveira-Cucolo JG, Rodrigues-Fleming GH, -Maniglia JV, et al. Glutathione S-transferase polymorphisms in head and neck squamous cell carcinoma treated with chemotherapy and/or radiotherapy. Asian Pac J Cancer Prev 2020;21:1637–44.
43. Lang J, Song X, Cheng J, Zhao S, Fan J. Association of GSTP1 Ile105Val polymorphism and risk of head and neck cancers: a meta-analysis of 28 case-control studies. PLoS One 2012;7:e48132.
44. Pasqualetti F, Gonnelli A, Cantarella M, Delishaj D, Molinari A, Ortenzi V, et al. Association of Glutathione S-Transferase P-1 (GSTP-1) rs1695 polymorphism with overall survival in glioblastoma patients treated with combined radio-chemotherapy. Invest New Drugs 2018;36:340–5.
45. Liblab S, Vusuratana A, Areepium N. ERCC1, XRCC1, and GSTP1 Polymorphisms and treatment outcomes of advanced epithelial ovarian cancer patients treated with platinum-based chemotherapy. Asian Pac J Cancer Prev 2020;21:1925–9.
46. Shen X, Wang J, Yan X, Ren X, Wang F, Chen X, et al. Predictive value of GSTP1 Ile105Val polymorphism in clinical outcomes of chemotherapy in gastric and colorectal cancers: a systematic review and meta-analysis. Cancer Chemother Pharmacol 2016;77:1285–302.
47. Chen J, Cao Q, Qin C, Shao P, Wu Y, Wang M, et al. GPx-1 polymorphism (rs1050450) contributes to tumor susceptibility: evidence from meta-analysis. J Cancer Res Clin Oncol 2011;137:1553–61.
48. Janicka A, Szymańska-Pasternak J, Bober J. Polymorphisms in the oxidative stress-related genes and cancer risk. Ann Acad Med Stetin 2013;59:18–28.
49. Laribi A, Aouf S, Gabbouj S, Bouaouinaa N, Zakhama A, Harizi H. Human glutathione peroxidase codon 198 variant increases nasopharyngeal carcinoma risk and progression. Eur Arch Otorhinolaryngol 2021;278:4027–34.
50. Dequanter D, Dok R, Koolen L, Vander Poorten V, Nuyts S. Prognostic significance of glutathione peroxidase levels (GPx1) in head and neck cancers. Front Oncol 2017;7:84.
51. Ban S, Konomi C, Iwakawa M, Yamada S, Ohno T, Tsuji H, et al. Radiosensitivity of peripheral blood lymphocytes obtained from patients with cancers of the breast, head and neck or cervix as determined with a micronucleus assay. J Radiat Res 2004;45:535–41.
52. Yu J, Huang Y, Liu L, Wang J, Yin J, Huang L, et al. Genetic polymorphisms of Wnt/β-catenin pathway genes are associated with the efficacy and toxicities of radiotherapy in patients with nasopharyngeal carcinoma. Oncotarget 2016;7:82528– 37.
53. Wang ZY, Chen LH, Fan Q, Yan WP, Chen YQ, Li QS, et al. Relationship between radiosensitivity of nasopharyngeal carcinoma and MDR1 gene polymorphism. Nan Fang Yi Ke Da Xue Xue Bao 2007;27:580–3.
54. Li Y, Zhu L, Yao H, Zhang , Kong X, Chen L, et al. Association of inflammation-related gene polymorphisms with susceptibility and radiotherapy sensitivity in head and neck squamous cell carcinoma patients in Northeast China. Front Oncol 2021;11:651632.
55. Seibold P, Hall P, Schoof N, Nevanlinna H, Heikkinen T, Benner A, et al. Polymorphisms in oxidative stress-related genes and mortality in breast cancer patients--potential differential effects by radiotherapy? Breast 2013;22:817–23.
56. Zhang JX, Wang ZM, Zhang JJ. Association of glutathione peroxidase-1 (GPx-1) rs1050450 Pro198Leu and Pro197Leu polymorphisms with cardiovascular risk: a meta-analysis of observational studies. J Geriatr Cardiol 2014;11:141–50.
57. Zmorzyński S, Świderska-Kołacz G, Koczkodaj D, Filip AA. Significance of polymorphisms and expression of enzyme-encoding genes related to glutathione in hematopoietic cancers and solid tumors. Biomed Res Int 2015;2015:853573.
58. Zhang CD, Yang Y, Chen HH, Zhang T, Wang Q, Liang Y, et al. RTPDB: a database providing associations between genetic variation or expression and cancer prognosis with radiotherapy- based treatment. Database 2018;2018:bay118.

APA	Benzeid R, amina g, Benchakroun N, El Benna N, GUENSI A, benider a, Tawfiq N, FILALI-MALTOUF A, El Mzibri M, Attaleb M, Khyatti M, chaoui i (2022). GSTP1 Ile105Val and GPX1 Pro198Leu Polymorphisms and Their Association with Response to Radiotherapy in Nasopharyngeal Carcinoma Patients. , 64 - 72. 10.14744/ejmo.2022.89238
Chicago	Benzeid Rajaa,amina gihbid,Benchakroun Nadia,El Benna Naima,GUENSI AMAL,benider abdellatif,Tawfiq Nezha,FILALI-MALTOUF Abdelkarim,El Mzibri Mohammed,Attaleb Mohammed,Khyatti Meriem,chaoui imane GSTP1 Ile105Val and GPX1 Pro198Leu Polymorphisms and Their Association with Response to Radiotherapy in Nasopharyngeal Carcinoma Patients. (2022): 64 - 72. 10.14744/ejmo.2022.89238
MLA	Benzeid Rajaa,amina gihbid,Benchakroun Nadia,El Benna Naima,GUENSI AMAL,benider abdellatif,Tawfiq Nezha,FILALI-MALTOUF Abdelkarim,El Mzibri Mohammed,Attaleb Mohammed,Khyatti Meriem,chaoui imane GSTP1 Ile105Val and GPX1 Pro198Leu Polymorphisms and Their Association with Response to Radiotherapy in Nasopharyngeal Carcinoma Patients. , 2022, ss.64 - 72. 10.14744/ejmo.2022.89238
AMA	Benzeid R,amina g,Benchakroun N,El Benna N,GUENSI A,benider a,Tawfiq N,FILALI-MALTOUF A,El Mzibri M,Attaleb M,Khyatti M,chaoui i GSTP1 Ile105Val and GPX1 Pro198Leu Polymorphisms and Their Association with Response to Radiotherapy in Nasopharyngeal Carcinoma Patients. . 2022; 64 - 72. 10.14744/ejmo.2022.89238
Vancouver	Benzeid R,amina g,Benchakroun N,El Benna N,GUENSI A,benider a,Tawfiq N,FILALI-MALTOUF A,El Mzibri M,Attaleb M,Khyatti M,chaoui i GSTP1 Ile105Val and GPX1 Pro198Leu Polymorphisms and Their Association with Response to Radiotherapy in Nasopharyngeal Carcinoma Patients. . 2022; 64 - 72. 10.14744/ejmo.2022.89238
IEEE	Benzeid R,amina g,Benchakroun N,El Benna N,GUENSI A,benider a,Tawfiq N,FILALI-MALTOUF A,El Mzibri M,Attaleb M,Khyatti M,chaoui i "GSTP1 Ile105Val and GPX1 Pro198Leu Polymorphisms and Their Association with Response to Radiotherapy in Nasopharyngeal Carcinoma Patients." , ss.64 - 72, 2022. 10.14744/ejmo.2022.89238
ISNAD	Benzeid, Rajaa vd. "GSTP1 Ile105Val and GPX1 Pro198Leu Polymorphisms and Their Association with Response to Radiotherapy in Nasopharyngeal Carcinoma Patients". (2022), 64-72. https://doi.org/10.14744/ejmo.2022.89238

APA	Benzeid R, amina g, Benchakroun N, El Benna N, GUENSI A, benider a, Tawfiq N, FILALI-MALTOUF A, El Mzibri M, Attaleb M, Khyatti M, chaoui i (2022). GSTP1 Ile105Val and GPX1 Pro198Leu Polymorphisms and Their Association with Response to Radiotherapy in Nasopharyngeal Carcinoma Patients. Eurasian Journal of Medicine and Oncology, 6(1), 64 - 72. 10.14744/ejmo.2022.89238
Chicago	Benzeid Rajaa,amina gihbid,Benchakroun Nadia,El Benna Naima,GUENSI AMAL,benider abdellatif,Tawfiq Nezha,FILALI-MALTOUF Abdelkarim,El Mzibri Mohammed,Attaleb Mohammed,Khyatti Meriem,chaoui imane GSTP1 Ile105Val and GPX1 Pro198Leu Polymorphisms and Their Association with Response to Radiotherapy in Nasopharyngeal Carcinoma Patients. Eurasian Journal of Medicine and Oncology 6, no.1 (2022): 64 - 72. 10.14744/ejmo.2022.89238
MLA	Benzeid Rajaa,amina gihbid,Benchakroun Nadia,El Benna Naima,GUENSI AMAL,benider abdellatif,Tawfiq Nezha,FILALI-MALTOUF Abdelkarim,El Mzibri Mohammed,Attaleb Mohammed,Khyatti Meriem,chaoui imane GSTP1 Ile105Val and GPX1 Pro198Leu Polymorphisms and Their Association with Response to Radiotherapy in Nasopharyngeal Carcinoma Patients. Eurasian Journal of Medicine and Oncology, vol.6, no.1, 2022, ss.64 - 72. 10.14744/ejmo.2022.89238
AMA	Benzeid R,amina g,Benchakroun N,El Benna N,GUENSI A,benider a,Tawfiq N,FILALI-MALTOUF A,El Mzibri M,Attaleb M,Khyatti M,chaoui i GSTP1 Ile105Val and GPX1 Pro198Leu Polymorphisms and Their Association with Response to Radiotherapy in Nasopharyngeal Carcinoma Patients. Eurasian Journal of Medicine and Oncology. 2022; 6(1): 64 - 72. 10.14744/ejmo.2022.89238
Vancouver	Benzeid R,amina g,Benchakroun N,El Benna N,GUENSI A,benider a,Tawfiq N,FILALI-MALTOUF A,El Mzibri M,Attaleb M,Khyatti M,chaoui i GSTP1 Ile105Val and GPX1 Pro198Leu Polymorphisms and Their Association with Response to Radiotherapy in Nasopharyngeal Carcinoma Patients. Eurasian Journal of Medicine and Oncology. 2022; 6(1): 64 - 72. 10.14744/ejmo.2022.89238
IEEE	Benzeid R,amina g,Benchakroun N,El Benna N,GUENSI A,benider a,Tawfiq N,FILALI-MALTOUF A,El Mzibri M,Attaleb M,Khyatti M,chaoui i "GSTP1 Ile105Val and GPX1 Pro198Leu Polymorphisms and Their Association with Response to Radiotherapy in Nasopharyngeal Carcinoma Patients." Eurasian Journal of Medicine and Oncology, 6, ss.64 - 72, 2022. 10.14744/ejmo.2022.89238
ISNAD	Benzeid, Rajaa vd. "GSTP1 Ile105Val and GPX1 Pro198Leu Polymorphisms and Their Association with Response to Radiotherapy in Nasopharyngeal Carcinoma Patients". Eurasian Journal of Medicine and Oncology 6/1 (2022), 64-72. https://doi.org/10.14744/ejmo.2022.89238